Upcoming Webinar
Updates in Breast Cancer: Antibody-Drug Conjugates and Cyclin-Dependent Kinase Inhibitors
Date: June 15, 2026 | 2:00 PM
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
ADCs and CDK4/6 inhibitors continue to reshape breast cancer treatment across multiple disease settings. As indications expand and treatment approaches evolve, oncology teams are increasingly focused on balancing efficacy, tolerability, and long-term patient management.
In this CE-accredited session, Siân Behrendt-McLeroy, PharmD, MS (Texas Oncology), reviews
- The evolving role of CDK4/6 inhibitors in HR-positive breast cancer, including practical strategies to optimize tolerability in the adjuvant setting
- The expanding use of trastuzumab deruxtecan and its impact on treatment decisions across HER2-positive breast cancer
- Emerging evidence supporting the efficacy and safety of ADCs in metastatic triple-negative breast cancer
- Practical approaches for identifying, monitoring, and managing clinically significant adverse events associated with ADCs and CDK4/6 inhibitors
1.0 CE credit hours are available for pharmacists and pharmacy technicians.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
Upcoming Webinar
Updates in Breast Cancer: Antibody-Drug Conjugates and Cyclin-Dependent Kinase Inhibitors
June 15, 2026 | 2:00 PM